Message

From: CFD-SRT [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=3D7963607C714138900DD470D99B1174-CFD-SRT]

Sent: 8/5/2019 4:28:00 AM

To: Steven D. Bennett [sbennett@thehcpa.org]

Subject: RE: TIME-SENSITIVE - IMPORTANT TSCA SACC Member Request for responses to 4 Questions regarding

"Impartiality": 5 chemical risk evaluations that will be reviewed by the TSCA SACC

Thanks! I'll count you in. Stay-tuned for more information.

Regards, Sharlene

Sharlene R. Matten, Ph.D.
Senior Biologist
Office of Science Coordination and Policy
Exposure Assessment, Coordination, and Policy Division
U.S. Environmental Protection Agency
1200 Pennsylvania Ave., NW
Washington D.C. 20460

e-mail: matten.sharlene@epa.gov

Tel: 202-564-0130

From: Steven D. Bennett <sbennett@thehcpa.org>

Sent: Saturday, August 3, 2019 7:55 AM **To:** CFD-SRT < CFD-SRT@epa.gov>

Cc: Knott, Steven <Knott.Steven@epa.gov>; Gibson, Tamue <Gibson.Tamue@epa.gov>; Bloomer, Bryan <Bloomer.Bryan@epa.gov>; Hughes, Hayley <hughes.hayley@epa.gov>; Peterson, Todd <Peterson.Todd@epa.gov> Subject: RE: TIME-SENSITIVE - IMPORTANT TSCA SACC Member Request for responses to 4 Questions regarding "Impartiality": 5 chemical risk evaluations that will be reviewed by the TSCA SACC

My responses to the questions are attached. Happy to clarify any responses as needed

I am available for both the September and October dates

thanks

Steven Bennett, Ph.D.

Senior Vice President of Scientific Affairs Floor Care Division Staff Executive Pest Management Products Division Staff Co-Executive HCPA Consumer Product Ingredients Dictionary

XPAND 2019 – HCPA's Annual Meeting

Shift Your Mindset. Enable Change. Deliver the Future.

Marriott Harbor Beach Resort & Spa December 8-11, 2019 | Fort Lauderdale, FL VIEW EVENT INFORMATION & REGISTER



1667 K Street NW, Suite 300 | Washington, DC 20006

Direct: 202-833-7330 - Office: 202-872-8110





CONFIDENTIALITY NOTICE: This e-mail message (including any attachments) contains information from the Household & Commercial Products Association (HCPA) and is covered by the Electronic Communications Privacy Act, 18 U.S.C. §§ 2510-21, and is intended only for the named recipient (or recipients) and HCPA member companies. This e-mail, including any attachments or hyperlinks within it, may contain information that is confidential or otherwise protected from disclosure. If you are not the intended recipient of this email, you are not entitled to use, disclose, distribute, copy, print, disseminate or rely on this email in any way. Even if you are the intended recipient or a HCPA member company, you may not distribute, disclose or otherwise disseminate this email or its attachments outside the membership of HCPA, without HCPA's prior written consent.

From: CFD-SRT <<u>CFD-SRT@epa.gov</u>>
Sent: Thursday, July 25, 2019 6:15 PM

Cc: Knott, Steven < Knott.Steven@epa.gov>; Gibson, Tamue < Gibson.Tamue@epa.gov>; Bloomer, Bryan < Bloomer.Bryan@epa.gov>; Hughes, Hayley < hughes.hayley@epa.gov>; Peterson, Todd < Peterson.Todd@epa.gov>

Subject: TIME-SENSITIVE - IMPORTANT TSCA SACC Member Request for responses to 4 Questions regarding

"Impartiality": 5 chemical risk evaluations that will be reviewed by the TSCA SACC

Importance: High

Greetings!

I've addressed this message to all 21 current TSCA SACC members, "bcc," to avoid inadvertent replies to all.

Thank you again for your participation on the TSCA SACC.

The TSCA SACC has a very busy schedule in 2019 with meetings scheduled from June through December 2019. On December 19, 2016, EPA published a list of 10 chemical substances that are the subject of the Agency's initial chemical risk evaluations, as required by TSCA § 6(b)(2)(A). The docket numbers, problem formulations, scope documents and supplemental documents for the 10 chemical substances that EPA initiated the risk evaluation process for in December 2016 can be found here:

- Pigment Violet 29 (TSCA SACC meeting, June 2019)
- 1, 4 Dioxane (TSCA SACC meeting, July 29-Aug 2, 2019)
- Cyclic Aliphatic Bromide Cluster (HBCD) (TSCA SACC meeting, July 29-Aug 2, 2019)
- 1-Bromopropane TBD
- Methylene Chloride TBD
- N-Methylpyrrolidone TBD
- Perchloroethylene TBD
- Trichloroethylene TBD
- Carbon Tetrachloride TBD
- Asbestos TBD

Future meetings will focus on the Agency's draft risk evaluation for the remaining seven (7) chemicals: 1-bromopropane, methylene chloride, N-Methyl-2-pyrrolidone (NMP), perchloroethylene, trichloroethylene, carbon tetrachloride, and asbestos.

For planning purposes, please respond to the four questions regarding "impartiality" with respect to 1-bromopropane, methylene chloride, N-Methyl-2-pyrrolidone (NMP), perchloroethylene, and trichloroethylene (see Table below and word file attached). In addition, please indicate your availability for the following dates September 9-13, 2019 and October 21-25, 2019. A public announcement of the specific draft chemical risk evaluations for the September meeting will be published with the next 2 weeks; however, we need to make sure that there is a quorum of TSCA SACC members and adequate representation of expertise (additional ad hoc members) to address the Agency's charge before the official announcement is published. I know many of you will be traveling to the upcoming TSCA SACC meeting on 1,4-dioxane and HBCD, July 29-August 2, 2019. Time is of the essence. Please contact me if you have questions or concerns.

Thank you.

Sharlene (mobile: 240-286-4365 (Fridays); office: 202-564-0130)

Sharlene R. Matten, Ph.D.
Senior Biologist
Office of Science Coordination and Policy
Exposure Assessment, Coordination, and Policy Division
U.S. Environmental Protection Agency
1200 Pennsylvania Ave., NW
Washington D.C. 20460

e-mail: matten.sharlene@epa.gov

Tel: 202-564-0130

Questions	1- Bromopropane	Methylene Chloride	N-Methyl- 2- pyrrolidone (NMP)	Perchloroethylene	Trichloroethylene
(1) Do you know of any reason that you might be unable to provide impartial advice on the matter to come before the panel/committee/subcommittee or any reason that your impartiality in the matter might be questioned?					

(2) Have you had any previous involvement with the review document(s) under consideration including authorship, collaboration with the authors, or previous peer review functions? If so, please identify and describe that involvement.			
(3) Have you served on previous advisory panels, committees or subcommittees that have addressed the topic under consideration? If so, please identify those activities.			
(4) Have you made any public statements (written or oral) on the issue that would indicate to an observer that you have taken a position on the issue under consideration? If so, please identify those statements.			